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Abstract
Background: 13‐Deoxy, 5‐iminodoxorubicin (GPX‐150) is a doxorubicin (DOX) 
analog synthesized to reduce the formation of reactive oxygen species and the car-
diotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irrevers-
ible, cumulative dose‐dependent cardiotoxicity of DOX. In a preclinical chronic 
models and a phase I clinical study of GPX‐150, no irreversible, cumulative dose‐de-
pendent cardiotoxicity was demonstrated. Recent studies suggest that DOX cardio-
toxicity may be mediated, at least in part, by the poisoning of topoisomerase IIβ.
Patients and Methods: An open‐label, single‐arm phase II clinical study in meta-
static and unresectable soft tissue sarcoma (STS) patients was initiated to further 
evaluate the efficacy and safety of GPX‐150, including cardiac function, specifically 
left ventricular ejection fraction (LVEF).
Results: GPX‐150 was administered at 265 mg/m2 every 3 weeks for up to 16 doses 
with prophylactic G‐CSF until progression, death, or patient withdrawal from the 
study. GPX‐150 exhibited efficacy assessed as progression‐free survival (PFS) rates 
of 38% and 12% at 6 and 12 months and an overall survival rate of 74% and 45% at 6 
and 12 months. GPX‐150–treated patients did not develop any evidence of irrevers-
ible, cumulative dose‐dependent chronic cardiotoxicity. Toxicities included grade 3 
anemia, neutropenia, and one grade 4 leukopenia. Correlative analysis demonstrated 
that GPX‐150 was more selective than DOX for the inhibition of topoisomerase IIα 
over IIβ in vitro.
Conclusion: These results suggest future studies are warranted to further evaluate 
the clinical efficacy of GPX‐150 in STS, perhaps at doses higher than 265 mg/m2.
K E Y W O R D S
anthracyclines, cardiotoxicity, doxorubicin, GPX‐150, phase II, soft tissue sarcoma
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1 |  INTRODUCTION
Doxorubicin (DOX) as a single agent or in combination with 
ifosfamide has been the mainstay of first‐line treatment for ad-
vanced or metastatic soft tissue sarcoma (STS) for more than 
40 years.1-4 Recently, DOX in combination with olaratumab, 
a monoclonal antibody against platelet‐derived growth fac-
tor receptor alpha, demonstrated superiority over DOX alone 
and was granted accelerated approval by the FDA in 2016 as 
the first‐line therapy for metastatic STS.5 This was the first 
substantial change in chemotherapy for first‐line treatment of 
STS and solidifies the role of continued DOX use in STS. 
The continued role of DOX in STS and other cancers justifies 
the rationale for developing a safer and less cardiotoxic DOX 
analog. DOX can induce a chronic, irreversible cumulative 
cardiotoxicity that occurs in approximately 10% of patients, 
which limits its clinical utility.6 The irreversible cardiotox-
icity is dependent on the cumulative dose, which limits cu-
mulative DOX use below a dose of 350‐500 mg/m2. Even 
with early intervention with Angiotensin‐converting enzyme 
(ACE) inhibitors and beta blockers, not all patients recover 
within 5 years from the cardiotoxicity that develops after 
completion of DOX therapy.6 Cardiotoxicity also impairs the 
clinical use of DOX in combination with other chemothera-
peutic agents such as paclitaxel and trastuzumab, even when 
the combination improves the clinical outcome.7-12
The predominant theory for irreversible, cumulative DOX 
cardiotoxicity has evolved over many years and is believed to 
result from a quinone‐derived reactive oxygen species (ROS) 
and the formation of the cardiotoxic metabolite, doxorubi-
cinol, in cardiac myocytes.13-18 More recently, an additional 
mechanism has been purported to contribute to chronic DOX 
cardiotoxicity related to inhibition of topoisomerase IIβ that 
is expressed in the adult heart.19 GPX‐150 was specifically 
engineered to reduce or prevent cardiac ROS and doxorubici-
nol formation. In addition, GPX‐150 has been recently shown 
to spare inhibition of human topoisomerase IIβ in isolated in 
vitro decatenation assays.20
Preclinical studies demonstrated that GPX‐150 did not 
cause a chronic irreversible cardiotoxicity and the pharma-
cokinetics and cardiac effects of GPX‐150 were evaluated in 
a phase I clinical trial.20,21 This phase I clinical trial was a 
dose‐escalation study designed to determine the pharmaco-
kinetics and maximum tolerated dose (MTD) of GPX‐150. 
The results from the trial demonstrated no cardiotoxicity in 
24 patients, including four patients who had been previously 
treated with anthracyclines. The MTD was determined by 
neutropenia in the absence of granulocyte colony stimulating 
factors. GPX‐150 demonstrated stable disease in five out of 
seven patients, including three patients with STS. This pro-
vided the rationale for a phase II single‐arm, open clinical 
trial with GPX‐150 in patients with STS to evaluate progres-
sion‐free rate (PFS) with comparison to historical DOX PFS 
in STS. In addition, this provided the opportunity to evaluate 
the safety, including that of irreversible, cumulative cardio-
toxicity, of up to 16 cycles of GPX‐150 administered every 
3 weeks at the MTD defined in the phase I clinical trial.
2 |  PATIENTS AND METHODS
2.1 | Patients
The study population consisted of patients with metastatic 
or locally advanced unresectable STS. Individuals (age 
≥18 years) with histological documentation reviewed by in-
stitutional sarcoma pathologists at their treating institutions 
of advanced and/or metastatic STS of intermediate or high 
histologic grade for which an anthracycline was an appropri-
ate therapy and who gave informed written consent according 
to Food and Drug Administration and institutional guidelines 
were eligible. The patients could not have received prior 
chemotherapy for their current sarcoma, except for gemcit-
abine and/or docetaxel as adjuvant therapy completed at least 
6 months prior to the first planned dose of GPX‐150. Patients 
with the following sarcoma subtypes were excluded from the 
study: well‐differentiated liposarcoma or atypical lipomatous 
tumor, embryonal or alveolar rhabdomyosarcoma, Ewing's 
sarcoma, gastrointestinal stromal tumor (GIST), dermatofi-
brosarcoma protuberans, alveolar soft part sarcoma, solitary 
fibrous tumor, clear cell sarcoma, kaposi sarcoma, extraskele-
tal myxoid chondrosarcoma, PEComa (perivascular epithelial 
cell tumor), myoepithelioma/mixed tumor, sarcomas arising 
from bone or cartilage (chondrosarcoma, osteosarcoma, chor-
doma), or any patient that was eligible for curative intent ther-
apy. Patients who underwent radiotherapy to greater than 25% 
of bone marrow volume were also excluded from the study.
Other inclusion criterion included disease that was mea-
surable using RECIST 1.1 and an ECOG performance status 
of 0‐2. Patients were also required to have adequate cardiac 
function with left ventricular ejection fraction (LVEF) above 
the institution's lower limit of normal and QTcF ≤450 msec 
for males or 470 msec for females. Patients also agreed to use 
a highly reliable method of birth control for the duration of 
the study and women of childbearing potential had a serum 
pregnancy test performed within 28 days prior to the first day 
of GPX‐150 dosing.
Patients were required to have adequate bone marrow, 
liver, and renal function (absolute neutrophil count [ANC] 
>1500/mm3, platelet count > 100 000/mm3, total biliru-
bin <1.5 × ULN, ALT or AST < 2.5 × ULN [upper limit 
of normal; for subjects with documented liver metastases, 
ALT and AST < 5 × ULN], serum creatinine < 1.5 x ULN, 
international normalized ratio [INR] or activated partial 
thromboplastin time [PTT] ≤1.5 × ULN, if not therapeu-
tically anticoagulated and serum albumin > 3.0 gm/dL). 
Additionally, eligible patients could not have congestive heart 
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failure greater than Class II New York Heart Association 
functional classification, pericarditis, myocardial infarction 
within 6 months, or symptomatic coronary artery disease, ac-
tive infection requiring systemic antibacterial/antibiotic, anti-
fungal, or antiviral therapy or documented metastases to the 
brain or meninges. Other criteria for patient exclusion were 
any malignancy other than STS within the last 5 years prior 
to screening, with the exception of cervical carcinoma in situ, 
basal cell carcinoma, or superficial bladder tumors that were 
successfully and curatively treated with no evidence of recur-
rent or residual disease, currently pregnant or nursing women 
or known allergy to any of the study drugs or their excipients.
2.2 | Study design
The primary objective was to determine the efficacy of 
GPX‐150 administered intravenously once every 3 weeks 
to patients with STS as determined by progression‐free rate 
(PFR) at 12 months of treatment and to describe the safety 
profile of GPX‐150. The secondary objective was to describe 
the effects of GPX‐150 on STS as assessed by secondary ef-
ficacy measures: (a) PFR at 6 months, (b) progression‐free 
survival (PFS, defined as time to disease progression or 
death, (c) time to progression (TTP), (d) overall survival 
(OS), defined as time to death, (e) tumor response defined 
as complete response (CR), partial response (PR), or stable 
disease (SD), (f) duration of response, (g) duration of overall 
response (CR or PR), (h) best response during study, and (i) 
duration of best response.
2.3 | Drug formulation and administration
GPX‐150 for injection was supplied as a lyophilized pow-
der formulation in sterile 50‐mL amber glass vials containing 
50 mg of the drug (±15%) and 250 mg of lactose monohy-
drate. The actual amount of GPX‐150 for injection per vial 
was measured and reported on a certificate of analysis (COA) 
prepared for each manufacturing lot. Pharmacists were in-
structed to refer to the COA accompanying each shipment of 
GPX‐150 for the amount of investigational product in each 
vial in order to calculate dose volumes. Vials were protected 
from light and stored between −25° and −10°C (−13° and 
14°F). The lyophilized powder was reconstituted by the addi-
tion to the vial of 40 mL of 0.9% sodium chloride injection. 
The vial was shaken and the contents were completely dis-
solved after a period of 30 minutes at room temperature. Sites 
were instructed that the reconstituted product should be used 
promptly 30 minutes after reconstitution and no more than 
22 hours following reconstitution.
GPX‐150 was administered at a starting dose of 265 mg/m2. 
Sequential dose reductions to 200 mg/m2 and then to 150 mg/
m2 were allowed based on predetermined guidelines. The undi-
luted calculated dose was added to an intravenous (IV) bag for 
administration via a constant infusion pump at an infusion rate of 
2 mL/min through IV tubing. The IV tubing was flushed with an 
infusion of 0.9% sodium chloride for injection. The IV tubing was 
attached to a central line or angiocath inserted into a large vein. 
A dose of GPX‐150 was administered every 21 days (1 cycle). 
Treatment continued for 16 cycles, or until radiographically con-
firmed disease progression, death, or unacceptable toxicity.
Based on the phase I clinical study, it was expected that 
the dose limiting toxicity of GPX‐150 is myelosuppression. 
Therefore, G‐CSF was used in all subjects. Primary prophy-
laxis with G‐CSF was initiated after dose 1 and prophylaxis 
or treatment was administrated by the investigators according 
to ASCO guidelines.22
A continuation of dosing (compassionate use) past one 
year was allowed. Prior to initiation of the first post‐cycle 
16 dose, all end of study radiographic studies and tumor as-
sessments were performed before the initiation of continued 
dosing. Radiological studies and tumor assessments were 
performed every 9 weeks during the dosing continuation pe-
riod. Patients continued to receive doses of GPX‐150 every 
3 weeks for a maximum of eight additional cycles or until ra-
diographically demonstrated disease progression, unaccept-
able toxicity, or withdrawal of consent by the patient. Dosing 
could also be terminated before the maximum of eight cycles 
if there was an insufficient supply of GPX‐150. Upon com-
pletion of the dosing continuation period, all end of study 
final visit assessments were performed.
2.4 | Assessment of efficacy and 
adverse effects
The incidence, nature, and severity of adverse events 
(AEs) were determined according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(NCI:CTCAE) version 4.
2.5 | Statistics and IRB approvals
Data were summarized using descriptive statistics (number 
of subjects [n], mean, median, standard deviation, minimum, 
and maximum) for continuous variables. Categorical (discrete) 
variables were summarized using frequencies and percentages 
using MedCalc Version 18 (MedCalc Software bvba, Ostend, 
Belguim; http://medcalc.org;2018). Time to event variables 
were summarized using the number observed, number cen-
sored, median, and 25th and 75th percentiles from Kaplan‐
Meier (KM) curves. Data were summarized using descriptive 
statistics (number of subjects [n], mean, median, standard de-
viation, minimum, and maximum) for continuous variables. 
Categorical (discrete) variables were summarized using fre-
quencies and percentages. Mean values for QRS complex dura-
tion, QT interval, and QTcF were compared at screening and 
at final visit using Student's unpaired t test (significance level 
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was P < 0.05). LVEF mean values at screening and at final visit 
were compared using Student's unpaired t test (P < 0.05 was 
used as the level of significance).The trial was an open‐label 
single‐arm phase II study at three University sites, University 
of Iowa (Iowa City, IA) Northern University (Chicago, IL), 
and Washington University in Saint Louis, (St. Louis, MO), 
and was approved by their corresponding Institutional Review 
Boards. An informed consent was obtained from all individual 
participants included in the study. The trial was registered with 
ClinicalTrials.gov (Identifier No. NCT02267083).
2.6 | Correlative studies
2.6.1 | Human topoisomerase IIα and 
β assays
Four units of human topoisomerase IIα or IIβ (Lae Biotech 
International, Rockville, MD) were incubated for 60 minutes at 
room temperature in the presence of assay buffer (10 mmol/L 
Tris‐HCl, pH 8.0, 50 mmol/L NaCl, 0.1 mmol/L EDTA, 
50 mmol/L KCl, 5 mmol/L MgCl2, 15 µg/mL BSA, 0.2 mmol/L 
ATP), 3 ug/mL concatenated DNA (kinetoplast DNA (kDNA), 
a series or interlocking small rings of DNA; Profoldin, Hudson, 
MA), and various concentrations of DOX and GPX‐150 
(100 µmol/L to 100 nmol/L) in half log increments or vehicle. 
The topoisomerase enzyme was added last to the reaction mix-
ture to initiate the reaction. After 60 minutes, the reaction was 
stopped by addition of 5 mL stop solution (Profoldin, Hudson, 
MA) and the reaction was loaded onto a 96‐well filter plate 
(0.2‐µm PVDF membrane filter plate, Corning, Catalog #3504, 
Corning, NY) with an attached receiving plate. Plates were then 
centrifuged (4000 g) until all solution had passed through the 
filter. A quantity of 150 μL of rinse buffer (Profoldin, Hudson, 
MA) was loaded onto plates and centrifugation was repeated. 
Filter plate was then removed, and 50 μL of dye (Profoldin, 
Hudson, MA) was added to receiving plate. Each well was 
then excited at 485 nm and the intensity was read at 535 nm. 
Readings were then normalized to controls.
3 |  RESULTS
3.1 | Patients characteristics
The patient demographics are shown in Figure 1 and Table 
1. There were 22 patients in the safety population and 21 pa-
tients in the efficacy (intent to treat; ITT) population. Patients 
in the safety population received at least one dose of GPX‐150. 
Patients in the efficacy population received at least one tumor 
F I G U R E  1  Disposition and accountability of patients
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assessment after receiving a minimum of one dose of GPX‐150 
although two of the 21 patients died before their first tumor 
assessment after receiving one dose of GPX‐150 (Figure 1).
The average age of patients in the safety population was 
59.4 ± 13.6 years with a range of 30‐84 years. Thirteen 
patients were ECOG 0, 9 patients were ECOG 1, and no 
enrolled patients were ECOG 2. Fifteen subjects (68.2%) 
were male and seven (31.8%) were female. Twenty subjects 
(90.9%) were white and two subjects (9.1%) were Black/
African American. 9.1% of subjects identified as Hispanic 
or Latino. The individual sarcoma histology classifications 
of the patients are shown in Table 2.
3.2 | Responses, PFS, and OS
The PFR of GPX‐150 at 6 and 12 months was 38% and 12%, 
respectively. The KM curve for PFS for GPX‐150 is shown 
in Figure 2A and OS in Figure 2B. The response rates were 0 
Complete responses, 1, partial response and nine patients with 
stable disease. Patient response, time on treatment, number of 
doses, and cumulative dose for each patient are shown in Table 3.
3.3 | Safety
GPX‐150 was well tolerated in all patients including two pa-
tients who received 16 doses of GPX‐150 and one patient 
who received 20 doses of GPX‐150. Table 4 shows the per-
centage of patients with various side effects and severity of 
T A B L E  1  Patient characteristics
Characteristic N %
Safety population 22  







Mean ± SD 59.4 ± 13.6  
Range 30‐84  
ECOG status
ECOG 0 13 59
ECOG 1 9 41
ECOG 2 0 0
Race
White 20 90.9
Black/African American 2 9.1
Identified Hispanic or Latino 2 9.1
T A B L E  2  Histology classification of the tumors at baseline 
(safety population)
 n = 22
Adipocytic tumor—myxoid/round cell liposarcoma 2 (9.1%)
Adipocytic tumor—pleomorphic liposarcoma 1 (4.5%)
Carcinosarcoma 1 (4.5%)




Smooth muscle tumors (leiomyosarcoma) 5 (22.7%)
Tumor of peripheral nerves—malignant peripheral 
nerve sheath tumor
1 (4.5%)
Tumor of uncertain differentiation—synovial 
sarcoma
2 (9.1%)
Tumor of uncertain differentiation—undifferentiated 
sarcoma/sarcoma NOS
2 (9.1%)
Undifferentiated endometrial sarcoma 1 (4.5%)
F I G U R E  2  A. Kaplan‐Meier curve for progression free rate in STS patients receiving GPX‐150. B. Kaplan‐Meier curve for overall survival 
in STS patients receiving GPX‐150
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side effects for GPX‐150. GPX‐150 was not associated with 
significant alopecia or mucositis beyond grade 1 or with 
grade 3 or 4 nausea and vomiting.
3.4 | Cardiac safety
There was no overall trend for decreased LVEF as a func-
tion of cumulative dose in the safety population. The aver-
age LVEF at screening was 61.8 ± 6.5 (n = 22) and at the 
end of study was 58.4 ± 10.1 (n = 22) (not significant). The 
final visit mean LVEF was almost identical to the screening 
mean LVEF. There was a subset population of four subjects 
in which at least one abnormal LVEF below 50% occurred 
and could have been related to GPX‐150 administration. 
However, in all four subjects, all decreases in LVEF were 
transitory and returned to normal values and were not 
considered of clinical significance. The mean final LVEF 
(57.5 ± 2.6) in these four subjects was nearly identical to 
the mean screening LVEF (59.5 ± 2.6) and no subject de-
veloped clinical evidence of cardiotoxicity or heart failure.
As expected, no patient receiving GPX‐150 exhibited an 
abnormal ECG at any time during the study. The intervals 
were not prolonged or abnormal as a result of GPX‐150 ad-
ministration and QTcF values were not different between 
screening and the final visit in the safety population.
3.5 | Deaths during the study
Three patients died while on study. The first patient was di-
agnosed with high grade carcinosarcoma in 2015 and entered 
the GPX‐150 trial on 3 March 2015. While on vacation in 
Hawaii, he was hospitalized on 22 March 2015 for dehydra-
tion. Subsequent brain MRI showed four enhancing lesions 
in the right cerebellum and right occipital lobe. The investi-
gator considered this event as disease progression after one 
GPX‐150 dose. The patient died from recurrent carcinosar-
coma 9 days later on 31 March 2015. The second patient to 
die while on study had a medical history of leiomyosarcoma 
and received the first dose of GPX‐150 on 29 January 2015. 
On 3 February 2015, the patient developed febrile neutrope-
nia, anemia, and decreased lymphocyte count likely related 
to GPX‐150 administration. The patient received a reduced 
dose of GPX‐150 per protocol on 19 February 2015. On 15 
March 2015, the patient died at home from respiratory failure 
T A B L E  3  Extent of exposure to GPX‐150 (ITT population)
Subject no. Total days on treatment Doses received
Cumulative dose received 
(mg/m2) Tumor response
01‐002 126 6 1590 SD
01‐003 18 1 265 Died
01‐004 42 2 530 PD
01‐005 47 2 530 PD
01‐007 140 6 1590 SD
03‐001 231 11 2915 SD
03‐002 32 2 465 Died
03‐003 371 16a 5300 SD
03‐004 48 2 530 PD
03‐006 42 2 530 PD
03‐007 239 10 2650 PR; SD
03‐008 42 2 530 PD
03‐010 56 2 530 PD
03‐011 86 4 1060 SD
03‐012 126 6 1590 SD
03‐013 365 16 4240 SD
04‐002 42 2 530 Died
04‐003 365 16 4240 SD
04‐004 58 2 530 PD
04‐005 43 2 530 PD
04‐006 44 2 530 PD
PD, progressive disease; PR, partial response; SD, stable disease.
aThis subject continued dosing beyond the protocol‐specified number of doses and received a total of 20 doses of GPX‐150. This subject remained on study as a 
compassionate use subject for a total of 504 days on study. Median time on treatment was 56 days. 
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secondary to sarcoma not related to GPX‐150. This patient re-
ceived doses of GPX‐150 and had been on study for 32 days.
The third patient to die while on study was a patient with 
a medical history of liposarcoma and received two doses of 
GPX‐150 (17 March 2015 and 7 April 2015). The patient 
died on 14 May 2015 from disease progression of liposar-
coma as determined by the investigator.
3.6 | Correlative analysis
To assess the relative potency of DOX and GPX‐150 to in-
hibit topoisomerase IIα and β‐mediated decatenation of DNA, 
concentrations of DOX and GPX‐150 ranging between 0.1 
and 100 μmol/L were incubated with purified human topoi-
somerase Iiα sand IIβ and DNA at 37°C for 60 minutes. Table 
5 shows the IC50 values for DOX and GPX‐150 to inhibit 
topoisomerase IIα and IIβ. Quantitation of decatenation by 
the fluorescence method shows that DOX is approximately 
10 times more potent to inhibit topoisomerase IIα compared 
to IIβ. In contrast, GPX‐150 inhibited topoisomerase IIα but 
not IIβ. Thus, utilizing this methodology up to the concentra-
tion of 100 μmol/L, GPX‐150 was selective to inhibit topoi-
somerase IIα while DOX inhibited both topoisomerase IIα 
and IIβ isoforms.
4 |  DISCUSSION
There has been an intense effort over the last five decades to 
remove the cardiotoxicity of DOX while retaining its anti-
cancer activity or to develop cardioprotective strategies. The 
value of such an innovation is obvious with a decrease in the 
restriction in cumulative dosing and increasing the clinical 
utility in combination with other anticancer agents such as 
trastuzumab and paclitaxel.
Of the cardioprotective approaches, only dexrazoxane 
(Zinecard) has been approved by the FDA to attenuate 
DOX‐induced cardiotoxicity23 The mechanism of dexrazox-
ane cardioprotection is thought to relate to attenuated free 
radical formation via iron chelation and more recently it 
has been shown to be a catalytic inhibitor of topoisomerase 
IIβ, a mechanism recently implicated in the cardiotoxicity 
of DOX. However, its effect on cancer‐related outcomes 
remains controversial which has tempered FDA recom-
mendations for use with DOX.23 For example, one study 
demonstrated a cardioprotective effect in women with breast 
cancer but the objective response of DOX was attenuated 
in combination with dexrazoxane vs placebo (ie, 46.8% vs 
60.5%).24 Thus, the FDA has limited the use of dexrazoxane 
in patients with metastatic breast cancer who have received 
a cumulative dose of 300 mg/m2 or more of DOX.23
Another cardioprotective approach relates to how DOX is 
administered. Slow infusion of DOX appears to be less car-
diotoxic that rapid infusion. In one study, a 6‐hour infusion of 
DOX was less cardiotoxic than a 20‐minute infusion.25 The 


































T A B L E  5  IC50 (μmol/L) of DOX and GPX‐150 to inhibit the in 









GPX‐150 35.2 Not detectable
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mechanism may relate to decreased cardiac concentrations of 
DOX and the cardiotoxic metabolite, doxorubicinol.25
Other approaches have been directed to novel formulations 
such as PEGylated liposomal DOX,26 DOX conjugated to tar-
geted moieties such as transferrin (Hofmann et al, 2007) or 
DOX linked to a protein such as albumin (aldoxorubicin).27-30 
GPX‐150 is a novel approach in that structural changes to the 
DOX molecule itself were utilized to reduce or eliminate the ir-
reversible, cumulative dose‐dependent cardiotoxicity of DOX. 
In a preclinical study using a chronic rabbit model 20 and in a 
phase I clinical trial,21 GPX‐150 did not exhibit irreversible, 
cumulative dose‐dependent cardiotoxicity, even in patients pre-
viously treated with prior DOX or epirubicin. The results of 
this phase II study are consistent with the previous studies.
In a recent prospective study by Cardinale et al,6 2625 
DOX‐treated patients were followed for a median of 5.2 years 
after completion of DOX therapy. Two hundred and twenty‐
six patients (9%) developed cardiotoxicity with a median time 
of 3.5 months after completion of DOX therapy. The investi-
gators divided the cardiotoxic patients into three categories 
based on LVEF values; those who fully recovered to near pre‐
DOX LVEF, those who partially recovered, and those who 
did not recover LVEF function. Only 11% of patients made 
a full recovery to pre‐DOX values and it required an average 
of 4 years for the mean LVEF to return to pre‐DOX values, 
even with treatment using ACE inhibitors and beta blockers. 
Thus, in this study, DOX cardiotoxicity was manifest within 
median of 3.5 months after completion of DOX therapy (ap-
proximately 9.5 months after start of DOX administration) 
and remained at abnormal values (<50%) for a year or longer 
in approximately 90% of patients with chronic, cumulative 
dose‐dependent DOX cardiotoxicity. These findings are also 
in agreement with another study which reported clinical heart 
failure within 1 month after completion of DOX.31
The Cardinale 6 and von Hoff 31 findings of DOX cardio-
toxicity are in contrast to the results of the current phase II 
clinical trial with GPX‐150. Patients treated with GPX‐150 
had normal mean LVEF values not statistically different 
from their pre‐GPX‐150 values (61.8 ± 6.5 at screening 
vs 58.4 ± 10.1, Table 5) 1 month or more after completion 
of GPX‐150 treatment that was up to 1 year after starting 
GPX‐150 treatment in three patients. In four patients, where a 
low (<50%) LVEF was recorded sometime during the study, 
the LVEF values 1 month or more after the final GPX‐150 
dose was administered had returned to normal, pre‐GPX‐150 
values (59.5 ± 2.6 at screening, 57.5 ± 2.6 at the end of the 
study, Table 1). Thus, cardiotoxicity was not an issue for 
GPX‐150 in this phase II study despite 16 or more doses (cy-
cles) in three patients. In contrast, if DOX was administered 
at doses greater than 975 mg/m2, 55% of patients would be 
expected to develop congestive heart failure.31
If the cardiotoxicity of anthracyclines can be eliminated, 
the hope that continuous treatment with an anthracycline as 
opposed to a limited number of cycles would allow for im-
proved PFS and OS. Contemporaneously with the development 
of GPX‐150, aldoxorubicin is another anthracycline that is 
being developed for the treatment of sarcoma that has reduced 
cardiotoxiticy. Chawla et al published a randomized phase IIb 
trial of aldoxorubicin vs DOX and found that aldoxorubicin 
had a superior PFS without evidence of cardiotoxicity when 
compared to DOX.29 In this study, treatments were limited to 
six cycles for both drugs. This demonstrates the efficacy of in-
creased exposure of STS to anthracyclines. Given that this trial 
was likely performed with GPX‐150 at a dose that is below a 
true maximum tolerated dose, it will take subsequent trials to 
determine whether aldoxorubicin or GPX‐150 will become the 
lead anthracycline replacement of choice. Until then, further 
investigation into both compounds is needed.
The sample size in this study is too small to draw conclu-
sions about histologies associated with antitumor response 
or the transient fall in LVEF in the four patients in this study. 
Other factors besides GPX‐150 may have been responsible 
for a low LVEF recording. Nevertheless, these decreases 
in LVEF in GPX‐150–treated patients were not serious ad-
verse events and were transient, with LVEF subsequently 
returning to normal levels in all four subjects. Despite some 
subjects receiving GPX‐150 for up to 16 cycles, effects on 
cardiac function were of no clinical significance and there 
was no evidence of irreversible heart failure in any subject. 
In all instances, decreases in LVEF were transitory and 
self‐limited.
In this study, GPX‐150 demonstrated limited toxicity as 
seen from its safety profile. Apart from one patient who de-
veloped febrile neutropenia and severe leukopenia, there were 
no grade 4 toxicities reported and no grade 3 side effects apart 
from anemia (Table 4). Indeed, the toxicity profile of GPX‐150 
was better than with DOX as illustrated by a 2% occurrence of 
grade 4 and 6% occurrence of grade 3 mucositis with DOX32 
but there were no grade 3 or 4 mucositis toxicities observed 
with GPX‐150 in the current study (Table 4). Similarly, DOX 
caused a 21% grade 3 alopecia rate in one study33 but there 
were no grade 3 or 4 GPX‐150 patients with alopecia (Table 
4). Doxorubicin also caused 13% of patients to elicit grades 3 
and 4 nausea and vomiting32 while no GPX‐150–treated pa-
tient had grade 3 or 4 nausea or vomiting. This suggests that 
doses higher than 265 mg/m2 could be used in future studies 
possibly with even better efficacy outcomes. The dose chosen 
in the current study was based on the phase I clinical study in 
which GPX‐150 was administered in the absence of G‐CSF, 
which is not truly a maximum tolerated dose of this therapeu-
tic. In the original phase I, due to the lack of G‐CSF, 5 of 7 
patients at 265 mg/m2 required dose lowering due to neutrope-
nia, and this was called the MTD. In the current phase II study, 
G‐CSF was administered prophylactically and only one patient 
exhibited a neutropenia. Since neutropenia is not the dose lim-
iting toxicity for GPX‐150 in the presence of G‐CSF, higher 
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doses of GPX‐150 should be explored in STS and evaluated 
for better clinical efficacy outcomes.
The clinical benefit of GPX‐150 in the patient with STS 
must be conservatively examined due to the very small sam-
ple size in this study. First, two patients died rapidly thought 
they were thought by investigators to have at least a 3‐month 
OS at the time of study entry. If patients have chemorefractory 
rapidly progressive disease, as can happen with sarcoma, this 
can happen. This effect was also seen with the early deaths 
in the DOX arm of the Olaratumab trial.5 Second, when one 
examines the PFS at 6 months, we find a 38% clinical benefit 
rate which is equivalent to the control arm of the olaratumab 
trial in terms of benefit.5 In addition, there were two patients 
that were on this therapy for the planned 16 cycles without 
substantial toxicity. In a small trial, this is a sign of clini-
cal activity and benefit to the patients that received therapy. 
Finally, whether the lack of response rate (only one patient) 
is due to sample size, GPX‐150 dose, or another reason will 
have to await formal testing in a larger trial.
In conclusion, the results from this phase II clinical study 
indicate that GPX‐150 is better tolerated and has a better 
safety profile than DOX. Future studies will help to further 
define the clinical role of GPX‐150 in STS and other cancers.
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